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Abstract: It is proposed that select oligomers of polymer d-lactic acid (PDLA) will form a stereocomplex with l-lactate in vivo, 
 producing lactate deficiency in tumor cells. Those cancer cells that utilize transport of lactate to maintain electrical neutrality may cease 
to multiply or die because of lactate trapping, and those cancer cells that benefit from utilization of extracellular lactate may be impaired. 
Intracellular trapping of lactate produces a different physiology than inhibition of LDH because the cell loses the option of shuttling 
pyruvate to an alternative pathway to produce an anion. Conjugated with stains or fluorescent probes, PDLA oligomers may be an agent 
for the diagnosis of tissue lactate and possibly cell differentiation in biopsy specimens. Preliminary experimental evidence is presented 
confirming that PDLA in high concentrations is cytotoxic and that l-lactate forms a presumed stereocomplex with PDLA. Future work 
should be directed at isolation of biologically active oligomers of PDLA.
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Hypotheses
1. It is hypothesized that oligomers of d-lactic acid 
(PDLA) can cross the cell wall, form templated 
stereocomplexes  with  l-lactate,  and  can  inhibit 
cell  growth  of  susceptible  cancer  cells  through 
unchecked acidosis. These cells may not be able 
to expel hydrogen ions formed as a by product 
of glycolysis. It is also proposed that the PDLA 
oligomer~l-lactate  complex  would  cause  a 
decrease in extracellular lactate that would para-
lyze the lactate shuttle and possibly starve exterior 
cancer cells.
2. It is hypothesized that dextran or a similar poly-
mer  could  be  conjugated  to  PDLA  oligomers, 
increasing their relative concentration providing 
  amplification of #1.
3. It is hypothesized that PDLA oligomers could be 
conjugated  to  a  stain  or  fluorescent  probe  pro-
viding  rapid  histological  detection  of  lactate  in 
  tissue. This could be morphologically correlated 
by  pathologists  such  that  diagnostic  criteria  of 
“poorly, moderately, or well differentiated cancer” 
may be related to lactate concentration.
Introduction
In 1931 Otto Warburg was awarded the Nobel Prize in 
medicine for his pioneering work demonstrating gly-
colysis as the primary anaerobic glucose metabolism 
within cancer cells.1 Unfortunately, to date, a univer-
sal therapy has not emerged from his work. Since that 
time it has become apparent that not all cancer cells 
utilize glycolysis to produce ATP, but some utilize 
oxidative phosphorylation (Krebs cycle) to generate 
energy.2 More specifically, those cells in the interior 
of a tumor where the oxygen tension is lowest and the 
milieu more acidotic tend to utilize glycolysis while 
those  cells  in  the  periphery  where  oxygen  tension 
is higher tend to utilize oxidative phosphorylation.3 
Glycolysis generates protons that need to be trans-
ported out of the cell to avoid acid build up. Many 
of the hydrogen ions that are transported out of the 
cell are accompanied by lactate to maintain electrical 
neutrality. There are other mechanisms exclusive of 
lactate that generate anions to buffer the acid produc-
tion of glycolysis. These include metabolism of pyru-
vate to bicarbonate by hydration of CO2 catalyzed by 
various carbonic anhydrases and monocarboxylases.4 
Decreasing the intracellular lactate concentration may 
cause cell death from unchecked acidosis. The intra-
cellular pHs of the interior and exterior tumor cells 
are  similar  but  the  extracellular  fluid  surrounding 
the inner cells is orders of magnitude more acidic.5 
It has been shown that a lactate shuttle exists between 
inner and outer cells where lactate is converted to 
pyruvate in the outer cells and then metabolized by 
oxidative phosphorylation to produce ATP to sustain 
cancer cells.6
The explanation of which tumor cells utilize gly-
colysis  is  more  complex  than  oxygen  availability. 
Rapid rates of energy production require the expedi-
ent but inefficient fermentation of glucose if there are 
insufficient or functionally abnormal mitochondria to 
process glucose through oxidative phosphorylation.2 
In addition to the metabolic effects of lactate in gly-
colysis, lactate has also been shown to contribute to 
tumor cell invasion and increased cell motility.7
More recent investigations have tried to sepa-
rate  lactate  production  from  the  hypoxic  effects 
on tumor growth by using genetic markers. These 
studies suggest lactic acidosis may be independent 
of oxygen tension and may be associated with a 
more favorable clinical outcome.8 If this concept is 
true then inactivation or trapping of lactate could 
worsen clinical outcome. In summary, just as Otto 
Warburg’s hypothesis is not universal to all cancers, 
lactate physiology in tumors probably has variable 
effect on viability,   progression and virulence in dif-
ferent cancers.
Brief Review of clinical Trials  
of chemotherapeutic Agents  
that Target Glucose Metabolism  
of Tumor cells
These  agents  include  Dichloroacetate  (DCA), 
  2-deoxyglucose (2-DG) and Lonidamine.
DCA
DCA is a pyruvate dehydrogenase activator, inhib-
iting the activity of pyruvate dehydrogenase kinase 
(PDK), and thus promoting the conversion of pyru-
vate to Acetyl-CoA.9 Treatment with DCA shifts the 
fate  of  pyruvate  from  glycolysis  to  mitochondrial 
oxidative  phosphorylation  which  is  likely  respon-
sible for its tumorcidal activity. DCA is an inhibitor 
of all four isoenymes of PDK.9 DCA has been used 
for the   treatment of congenital and acquired   lactic Select oligomers of PDLA inhibit cancer cells
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  acidosis  with  the  most  significant  long  term  side 
effect of reversible peripheral neuropathy but seda-
tion and elevation of hepatic transaminases have also 
been reported. The dose required to inhibit colorec-
tal cancer cells in vivo is estimated to be 5–10 times 
that used in treatment of lactic acidosis.9,10 Potential 
serum  therapeutic  doses  could  be  between  20  and 
50 mmole/L.9 In a number of studies DCA has been 
shown  to  be  a  tumoricidal  agent  and  has  reduced 
lactate levels in growth media in a dose-dependent 
  manner.11 Some favorable results have been reported 
in  five  patients  suffering  from  glioblastoma  multi-
forme  where  DCA  was  used  in  combination  with 
  surgery, temozolomide and   radiation.10 If PDLA is 
found to be tumoricidal, it is likely that PDLA will 
reduce  lactate,  by    trapping,  a  different  mechanism 
than proposed for DCA.   Possibly confounding the 
results of future testing of metabolic cancer agents, 
in some instances, the in vitro testing of DCA has not 
correlated with tumoricidal in vivo studies.10
2-DG
2-DG is a glucose analog that is a competitive inhibi-
tor of glucose. It is actively transported into cells and 
phosphorylated  into  2-DC  phosphate  (2-DC-P)  by 
hexokinase.11 Further metabolism of 2-DC-P is not 
possible  and  thus  glycolysis  is  limited.  2-DC  also 
has additional effects on protein glycoslyation sepa-
rate from its effects on glycolysis and it may enhance 
radionuclide cytotoxicity.12–14 In vivo studies (in mice) 
have shown that 2-DG is synergistic with adriamycin 
and  paclitaxel  in  transplanted  human  osteosarcoma 
and non small cell lung cancer.15,16 Combination che-
motherapy with 2-DG has been trialed in patients with 
glioblastoma.16 Because 2-DG is an analog of glucose 
it produces actions and side effects in cancer and non 
cancer cells. 2-DG may have proconvulsant actions.17
Lonidamine
Lonidamine,  a  derivative  of  indazole-3-carboxylic 
acid is an inhibitor of oxygen consumption and sup-
presses glycolysis in cancer cells probably through 
hexokinase suppression.15 Its action is non selective, 
but synergistic with other chemotherapeutic agents and 
it has been used in clinical trials for breast,   ovarian, 
lung  and  glial  cancers.15  The  major  complication 
observed  in  more  than  a  majority  of  patients  was 
myalgia that required lowering the dose.18
Other metabolic chemotherapeutic agents in the 
development pipeline include: 3-bromopyruvate, an 
inhibitor  of  hexokinase,  oxythiamine,  an  inhibitor 
of  transketolase  and  pyruvate  dehydrogenase,  and 
  6-aminonicotinamide,  an  inhibitor  of  the  pentose 
phosphate pathway.15,19 One major problem associated 
with present medications that target tumor metabo-
lism is that they also target normal cells. If PDLA is 
tumoricidal, it is speculated that cells having mito-
chondria with the capacity to shuttle pyruvate may 
be less affected than the subset of cancer cells that 
exclusively utilize glycolysis.
An explanation of the Unusual 
stereocomplex Formation  
of Lactic Acid
The discovery of unique racemic cystallites or ste-
reocomplex  formation  of  lactic  acid  was  reported 
by  Ikada  et  al  in  1987.20  Normally,  conglomerate 
racemic mixtures have a lower melting point than 
either enantiomer. However, when polymer   l-lactic 
acid  (PLLA)  and  PDLA  are  mixed  together  the 
melting  point  is  approximately  230  degrees  centi-
grade compared to their individual melting points of 
around 170 degrees centigrade. This reaction occurs 
in aqueous solution at room temperature without a 
catalyst.21,22
Since  stereocomplex  formations  occur  with 
various  blends  of  PDLA  and  PLLA,  I  speculated 
whether l-lactate (a monomer) would form a stereo-
complex with small PDLA oligomers of less than 
500   Daltons. If this were true, then there could be 
biologic applications of lactate trapping that could 
be used to target cancer cells. In order to prevent 
crystallized   oligomers, a degree of polymerization 
between 7 and 11   monomer units may be optimum, 
but this may not be the case in vivo.23 It has not been 
reported in the literature whether l-lactate will bind to 
PDLA   oligomers, however hetero-stereocomplexes 
of PDLA with levo amino acids polymers have been 
prepared.24 Also l-insulin has been reported to bind 
to PDLA and the clinical significance has not been 
reported.25
Because the proof of this concept is so dependent 
upon the proposed stereocomplex formed by PDLA 
oligomers and  l-lactate a  preliminary experimental 
section is appropriate:Goldberg
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pDLA Interferes with l-lactate 
Measurement (Methods and Results)
experiment #1
Forty mg of d-lactic acid (Sigma) was polymerized 
in  a  microwave  oven  according  to  the  method  of 
  Pandey and Aswath.26 The microwave polymerization 
was discontinued when the sample weighed 20 mg. 
Weight loss was from water during polymer esterifi-
cation and dehydration. In normal saline, at a temper-
ature of 37 degrees centigrade, a control solution of 
1 ml of l-lactic acid (50 mg/L) (Sigma) and separately 
1 ml of an experimental solution of 1 ml of 50 mg/L 
of l-lactic acid with 20 mg of PDLA were incubated 
for 2 hours. Measurement of l-lactate with L-Lactate 
Accuvin Test strips (Accuvin LLC, Napa, Ca), using 
stereospecific  lactate dehydrogenase  and  a  tetrazo-
lium color indicator, measured less l-lactate (inter-
ference) in the experimental sample as evidenced by 
colorimetric determination. Experimental sample vs. 
control measured 10 mg/L vs. 50 mg/L of l-lactate. 
Other relevant tests using similar methodology and 
D-Lactate Accuvin Test strips are as follows:
1. Interference when PLLA (100 mg) was added to a 
1 ml solution of 800 mg/L d-lactic acid.
2. No interference when 50 mg/L l-lactic acid solu-
tion was added to a 60 mg/L d-lactic acid solution 
(Table 1).
Conclusion  of  experiment  #1:  PDLA  in  normal 
saline solution decreases the measurement of l-lactate 
in normal saline solution and PLLA in normal saline 
solution decreases the measurement of d-lactate in 
normal saline solution.
experiment #2
After approval from the director of the clinical labo-
ratory and the chairman of the human studies com-
mittee  of  the  Durham  Veterans  Affairs  Medical 
Center and after vigorous exercise, 18 ml of blood 
was drawn from a human subject. The blood was col-
lected in three vials each containing sodium fluoride/
potassium oxalate. Tubes 1 and 3 were centrifuged 
at 3400 rpm for 15 minutes and the serum was frozen. 
To tube 2 was added and mixed 0.5 ml of a 1 ml nor-
mal saline solution containing a mixture of PDLA 
d-lactate oligomers with an initial weight of 100 mg 
of d-lactic acid that had been microwave polymerized 
with loss of 30 mg of water. Tube 2 was then centri-
fuged at 3400 rpm and the serum was frozen. Tubes 
1–3 containing serum were frozen at -5 degrees cen-
tigrade for 12 hours and then defrosted in an incuba-
tor at 37 degrees centigrade for 3 hours prior to assay. 
The tubes were then placed on ice and processed in 
the laboratory.
Serum was processed using the Siemens Dimen-
sion  Vista  System  Flex  reagent  cartridge  at  the 
  Durham Veterans Affairs Medical Center. Reference 
values of l-lactate are in the range of 0.4–2.0 mmol/L 
(Table 2).
Conclusion of experiment #2: PDLA of unknown 
molecular  weight  oligomers  reduces  the  measure-
ment of l-lactate in blood samples without addition of 
catalyst or heat.
Proposed reaction
l-lactate + PDLA =   PDLA~l-lactate complex  
+ PDLA + l-lactate
experiment #3
To determine the ability of PDLA and PLLA to medi-
ate cytotoxicity for malignant cells, freshly   isolated 
human  chronic  lymphocytic  leukemia  (CLL)  cells 
were cultured with the agents for 72 hours at 37 °C 
Table 1. interference reactions of PDLA and l-lactate and 
PLLA and d-lactate in saline.
l-lactate d-lactate
Test strip Test strip
l-lactic acid (0.05 mg) 50 mg/L
l-lactic acid (0.05 mg) + 
PDLA (20 mg)
10 mg/L
d-lactic acid (0.8 mg) 800 mg/L
d-lactic (0.8 mg) acid + 
PLLA (100 mg)
not detected
d-lactic acid (0.05 mg) + 
l-lactic acid (0.06 mg)
50 mg/L
Table 2. PDLA decreases measurement of l-lactate in blood. 
Tube l-lacate conc. pDLA l-lactate conc. 
with dilution
1 9.1 mmol/L 0 9.1 mmol/L
2 7.0 mmol/L 0.5 ml 7.58 mmol/L
3 8.6 mmol/L 0 8.6 mmol/LSelect oligomers of PDLA inhibit cancer cells
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in 5% carbon dioxide/95% air using SFM tissue 
culture  medium  (Invitrogen,  Carlsbad,  CA).  The 
cells were cultured in triplicate with eight 2-fold dilu-
tions  of  the  agents  (from  2.000  to  0.016  mg/mL). 
Cytotoxicity  was  determined  with  an  assay  using 
the    tetrazolium-based  compound  MTS  (Promega, 
  Madison, WI) [as has been done before].27
Conclusion of experiment #3: The studies demon-
strated cytotoxicity for the CLL cells, with the mean 
effective dose for 50% cytotoxic effect of 1.30 mg/mL 
for PDLA (1.93 and 0.66 mg/mL in patients A and B), 
and 2.14 mg/mL for PLLA (2.65 and 1.63 mg/mL in 
patients A and B). Thus, the PDLA was effective at 
a lower concentration than PLLA. However, a rela-
tively high concentration was required for both of 
these  for  the  anti-leukemia  effects.  If    lactate  trap-
ping was the cause of cytotoxicity, probably PDLA 
contains a large number of inactive oligomers mixed 
with one or more active oligomer(s).
Stereocomplex model  
of PDLA and l-lactate
The beta helix strand formed by PDLA oligomers 
could template for l-lactate because the lactate anion 
is attracted to the carbonyl of the ester which car-
ries a partial positive charge because of the inductive 
effects of the adjacent oxygen molecules.   Hydrogen 
  bonding  could  exist  between  the  OH  group  of 
  l-lactate and the ester oxygen of oligomers of PDLA. 
With these attractions, the methyl groups of PLDA 
and lactate are favorably oriented with minimal steric 
effects. This complex which has been more specifi-
cally named a homo-stereocomplex is probably dis-
tinct from the stereo PLDA~PLLA complex. At this 
time it is not possible to determine the minimum size 
oligomer of PDLA that would be needed to complex 
intracellular l-lactate, but the size could be less than 
500 Daltons (Fig. 1).
Discussion of experimental section
The  experimental  section  supports  my  hypothesis 
that  PDLA  oligomers  form  a  stereocomplex  with 
l-lactate. The reaction occurs spontaneously in both 
normal  saline  and  plasma  (delta  G  negative  and 
Kequilibrium greater than 1). With the present data, it 
is not possible to predict any other variables of the 
reaction  since  the  molecular  weight  of  the  poly-
mer  is  an  unknown.  Molecular  simulations  could 
provide    additional  information  about  PDLA  oli-
gomers and l-lactate binding. Assuming that active 
size oligomer(s) are mixed in the microwave PDLA 
  samples, separation of the polymer and data from iso-
thermal titration calorimetry could determine which 
oligomer(s) are active as well as the reaction kinet-
ics. Separation of the polymer to oligomers less than 
500 Daltons (162, 234, 306, 378, 450 corresponding 
to 3x, 4x, 5x, or 6x d-lactate monomers respectively) 
may  be  the  ideal  weights  for  biologic  application 
assuming that rapid plasma hydrolysis does not occur 
in vivo and multiple binding sites exist for l-lactate to 
complex with PDLA oligomers (Table 3).
estimation of Three compartment 
(Blood, extracellular Tumor, 
Intracellular Tumor) pDLA 
concentrations
The size, charge and lipophilic properties of the PDLA 
oligomers will mostly determine the   likelihood that 
Figure 1. l-lactate (white) binds (yellow) to PDLA oligomers (green).
Table  3.  PDLA  oligomer  weights  and  hydrogen  bond 
acceptors and donors.









2 162 5 1–2
3 234 7 1–2
4 306 9 1–2
5 378 11 1–2
6 450 13 1–2Goldberg
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it will be available in the extracellular space to com-
plex l-lactate. Using control values of pHe = 6.77 
(  extracellular pH) and pHp = 7.4 (plasma pH), assum-
ing no active transport, the ion distribution of PDLA 
with a pKa 3.86 would be approximately:5
plasma  without  a  catalyst  or  addition  of  heat  and 
there  is  some  cytotoxic  activity.  Evidence  has  not 
been presented that PDLA is tumoricidal in vivo. The 
optimum oligomer size(s), lipophilic properties (log P 
or Kow) and number of hydrogen bond donors or 
Thus the approximate plasma concentration of the 
anion oligomer would be 4.26x that of the extracel-
lular concentration.
The size, charge and lipophilic properties of the 
oligomer will mostly determine the likelihood that it 
will be available in the cytosol to complex l-lactate. 
However, the acid milieu of the extracellular com-
partment surrounding the tumor will aid in intracel-
lular ion trapping of PDLA. Using control values of 
pHe = 6.77 (extracellular pH) and pHi = 7.17 (intrac-
ellular pH), assuming no active transport, the effects 
of intracellular ion trapping of PDLA with a pKa 3.86 
would be approximately:5
Thus the approximate intracellular concentration of 
the anion oligomer would be 0.398x that of the extra-
cellular concentration. The [PDLAp
-]/[PDLAi
-] = 1.7 
(plasma concentration to intracellular concentration). 
Since lactate concentration in some aggressive can-
cers may range between 10–12.9 micromoles/gm, ion 
trapping effects may have clinical importance.28,29
Discussion
Evidence has been presented that PDLA of unknown 
molecular weight oligomers will spontaneously form 
a  complex  with  l-lactate  in  aqueous  solution  and 
pHp = 3.86 + log [PDLAp
-]/[PDLAp] {capillary} pHe = 3.86 + log [PDLAe
-]/[PDLAe]
3.54 = log [PDLAp
-]/[PDLAp] {capillary} 2.91 = log [PDLAe
-]/[PDLAe] Antilog of equations
3470 = [PDLAp








e] = 3470/814 = 4.26
  acceptors needs to be trialed to assess whether PDLA 
oligomers  of  2–4  monomers  (possibly  compatible 
with Lipinski’s rule of 5 criteria) will complex intrac-
ellular l-lactate and be lead compounds.30
How could pDLA Oligomers  
be Useful Antitumor Agents?
It is possible that some cancers may respond to ste-
reocomplex lactate trapping and others not. It is not 
clear from the experimental section what dose would 
be required to trap lactate in vivo and whether such 
a  dose  would  have  deleterious  side  effects.  The 
average  intra  tumor  lactate  concentration  reported 
in  aggressive  head  and  neck  tumors  and  cervical 
  cancers  has  been  reported  as  12.9  micromoles/gm 
and 10   micromoles/gm respectively.28,29,31,32
Without knowing the tissue density and location of 
the lactate (intra or extracellular) and kinetics of the 
stereocomplex  reaction  it  would  be  difficult  to  esti-
mate what concentration of PDLA oligomers would be 
potentially tumoricidal. However, multiple binding sites 
on oligomers less than 500 Daltons may be required for 
PDLA oligomers to be effective. Even if PDLA oligom-
ers were not tumoricidal, it could lower tissue lactate 
concentration and produce less virulent tumors.
pHe = 3.86 + log [PDLAe
-]/[PDLAe] {cell wall} pHi = 3.86 + log [PDLAi
-]/[PDLAi]
2.91 = log [PDLAe
-]/[PDLAe] {cell wall} 3.31 = log [PDLAi
-]/[PDLAi] Antilog of equations
814 = [PDLAe








-] = 814/2042 = 0.398Select oligomers of PDLA inhibit cancer cells
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How could pDLA be a Useful 
Diagnostic Agent?
With the addition of fluorescent or stain conjugates 
to PDLA, one may be able to detect lactate in biopsy 
specimens which have not been processed in usual 
fixatives. Because the stereocomplex reaction occurs 
in aqueous solution, it may be useful as an adjunct 
for  frozen  section  diagnosis.  Conjugated  PDLA 
attached to dextran or another polymer may improve 
the assay.33,34 Present methods to measure tissue lac-
tate levels are performed enzymatically with biolu-
minescent imaging.35 This technique is complex and 
expensive.
studies of cancer cells Lacking LDH 
Have Demonstrated that Lactic Acid is 
not the Major Mechanism Responsible 
for the Acid environment of Tumors 
so Why should complexing l-lactate 
Increase Acidity and Inhibit Tumor 
Growth?36
Complexing lactate does not produce the same physi-
ology as inhibiting lactate formation by a substrate 
deficiency or inhibition of LDH. When LDH is inhib-
ited the cell has the option of producing an anion 
through metabolism of pyruvate. This could include 
decarboxylation with formation of bicarbonate. When 
lactate is complexed the cancer cell loses the option 
to convert the pyruvate to an anion. Complexing may 
also drive the pyruvate-LDH-lactate reaction to the 
right since it would be unlikely that the complexed 
l-lactate would provide feedback inhibition for the 
reaction. Furthermore, changes in solubility or crys-
tallinity can occur in some stereocomplex reactions 
that may also drive the reaction forward.22 Essential 
to the role of PDLA in therapy, it is not known under 
what conditions the PDLA~l-lactate will dissociate.
could the pDLA~l-lactate Become  
a substitute Anion for l-lactate  
and be Transported Out of the cell?
Lactate is actively transported in and out of the cell by a 
monocarboxylate transporter. It would be unlikely that 
this transporter would recognize the   stereocomplex. 
Passive diffusion of the stereocomplex could occur, 
but  intracellular  formation  of  the  complex  may 
change the physical and chemical properties of the 
PDLA   oligomer especially with respect to solubility.
could cancer cells substitute 
Another Anion for l-lactate?
Yes. This would be part of its adaptive process to 
survive.
What Other Mechanisms are Available 
to the cancer cell to Maintain electric 
Balance and Restore its normal 
Acidic environment?
The cancer cell can restore its normal acidic environ-
ment through the vacuolar proton pump (V-  ATPase), 
sodium/proton exchanger (NHE), bicarbonate trans-
porters  (BCT)and  monocarboxylate  transporters 
(MCT).37,38 However, with any of these systems there 
still needs to be an anion expelled to maintain elec-
trical neutrality and the MCT and BCT systems still 
need a source for an anion which is likely pyruvate.
If pDLA Oligomers complex 
L-Lactate, But is Not Specific  
for cancer cells, What are the Likely 
consequences of Lactate Reduction?
This  is  presently  unknown,  however,  low  lactate 
levels are found in some patients with inherited lac-
tate  dehydrogenase  (LDH)  deficiencies.  Patients 
with deficiencies of H subunits of LDH are usually 
asymptomatic while those with M subunit deficien-
cies  may  complain  of  easy  fatigue  and  exertional 
myoglobinuria.39–41  Lowering  lactate  by  trapping 
with PDLA oligomers in normal cells will still allow 
alternative pathways for pyruvate such as conversion 
to Acetyl-CoA and decarboxylation. This could simi-
larly be a problem in tumor cells that have mitochon-
dria and capacity to redirect the pyruvate making it 
unlikely that PDLA would be a monotherapy.
What is the Bioavailability  
and Toxicity of pDLA?
PDLA  has  been  shown  to  dissolve  through  enzy-
matic hydrolysis over short periods of time in solu-
tions of phosphate buffered saline.42–45 Depending on 
the oligomer size and rate of PDLA ester hydroly-
sis it may be possible to design controlled released 
implanted  PDLA  for  chemotherapy.46–48  The  more Goldberg
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acidic   extracellular pH of the tumor milieu may favor 
sequestration of the non-ionic form of the oligomer.
The LD 50 for PDLA has not been established. 
PDLA~PLLA is used in medical devices and as coat-
ings  on  nanoparticles.49  Ringer’s  lactate    solution, 
containing a racemic mixture of lactate, is exten-
sively used as an intravenous fluid in clinics and 
hospitals  without  complications  from  d-lactate. 
Rare cases of d-lactic acidosis have been describe 
in patients with short bowel syndromes and usually 
present  with  neurotoxicity  and  acidosis  and  most 
of these patients are successfully treated with car-
bohydrate  restriction,  hydration  with  non  lactate 
fluids and sodium bicarbonate.50,51 If the etiology of 
the  d-  lactic  acidosis  is  from  bacterial  fermentation 
in the gut,   antibiotics may be prescribed. d-lactate 
  levels  greater  than  3  mmole/L  may  be  associated 
with symptoms.51 Since many factors such as degra-
dation rate of PDLA oligomers by esterases, d-lactate 
metabolism, protein binding and dosing schedules 
may affect PDLA oligomer plasma concentration it 
is difficult to predict if d-lactate derived from PDLA 
will be toxic. D-lactate is a naturally occurring sub-
stance, ingested daily, and metabolized to a limited 
degree by humans.
can pDLA Oligomers selectively  
Bind to Lactate Associated with 
cancer and not to normal cells?
Probably not, since lactate is present in normal cells, 
interstitial  fluid,  plasma  and  cerebral  spinal  fluid. 
  However, the extra and intra cellular pH gradients 
associate  with  some  forms  of  cancer  may  prefer-
entially  increase  concentrations  of  the  oligomer. 
  Furthermore,  non  cancer  cells  containing  mito-
chondria can neutralize the proton load of glycoly-
sis through alternative pathways such as oxidative 
  phosphorylation that may not be available in many 
cancer cells.
How could pyruvate Levels change 
With Formation of the pDLA~l-lactate 
complex?
It is possible that decreased levels of pyruvate could 
destabilize hypoxia-inducible factor (HIF) as well as 
decrease the shunting of pyruvate for lipid and nucleic 
acid synthesis.19
Would pDLA Oligomers be  
a Monotherapy for cancer?
Probably it would not. Other agents may need to   target 
the acid lowering effects of BCI, MCT, V-ATPase 
and NHE. In addition, commonly used antineoplas-
tic therapies most likely would need to be continued. 
The adaptation response of tumor cells to therapies 
has been mathematically modeled by Gatenby RA 
et al and timing of therapy with PDLA could be an 
important factor.7
What is the Likely Fate of the pDLA 
Oligomer~l-lactate complex?
The answer is pure speculation, but the fate may be 
different if there are solubility changes, cell death, or 
inhibition of cell growth.
What are some Likely Flaws  
in this concept?
1. For unknown reasons PDLA oligomers may not 
inhibit the in vitro growth of tumor cells, however 
agents that target metabolic pathways in cancer 
may be effective in vivo and not in vitro. In vivo 
testing may be required even if in vitro testing does 
not confirm tumoricidal activity.
2. More  formal  studies  may  show  that  the 
l-lactate~PDLA stereocomplex is non specific.
3. The quantities of PDLA and PLLA used in the 
experiments were exceptionally large and the dose 
required for complex formation may be toxic.
4. The l-lactate-PDLA oligomer stereocomplex may 
not occur in vivo because serum or intracellular 
esterases may hydrolyze PDLA oligomers making 
them ineffective.
5. Bioavailability or solubility prevents PDLA oligom-
ers from being effective.
6. Oligomers  of  PDLA  may  not  cross  the  cell 
membrane.
7. Cancer cells may adapt to intracellular l-lactate 
trapping and continue to grow in a more acidotic 
environment or another anion other than lactate is 
transported to the extracellular space to maintain 
electrical neutrality.
conclusion
One needs to be cautious interpreting the concepts and 
experimental findings in this paper. I set out to investigate Select oligomers of PDLA inhibit cancer cells
Perspectives in Medicinal Chemistry 2011:5  9
two major concepts: 1) A stereocomplex forms between 
PDLA  and  l-lactate.  2)  Trapping  lactate  will  inhibit 
tumor cell growth. Neither concepts were conclusively 
proven, but the concepts were supported by experiments 
with inefficient(high) concentrations of PDLA that very 
likely contain biologically active oligomer(s) that trap 
lactate as well as inactive oligomer(s).
Optimum  size  oligomers  of  PDLA  may  have 
potential as antitumor and diagnostic agents forming 
stereocomplexes with l-lactate. Complexing intrac-
ellular lactate may produce acidosis differently than 
decreasing  lactate  by  enzyme  inhibition  of  LDH 
where the potential to convert pyruvate to an anion 
exists. Even if every concept that has been presented 
is proven, it is unlikely that PDLA oligomers would 
be a monotherapy for treatment of cancer, but rather 
an  adjunct  to  present  therapies.  If  concentrations 
of  PDLA  oligomers  cannot  be  safely  tumoricidal, 
PDLA  oligomers  could  lower  tissue  lactate  levels 
possibly  decreasing  tumor  virulence.  Complexing 
l-lactate with the smallest size oligomer having mul-
tiple  binding  sites,  conforming  to  Lipinski’s  rules, 
balanced by the rate of plasma ester hydrolysis of 
PDLA   oligomers, may produce the best therapeutic 
response.    Stereocomplexes  are  unique  formations, 
when discovered and appreciated, may translate into 
medical therapies. I hope this paper will enlighten 
those in medicine of the potential that select PDLA 
oligomers may have as a useful agent in cancer and 
other medical therapies when the need to trap lactate 
is diagnostic or therapeutic. Further work in the labo-
ratory is enthusiastically encouraged to isolate, purify 
and conduct experiments to prove which oligomers of 
PDLA will be most beneficial.
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